Agenus Inc (AGEN) 6.14 $AGEN Antigenics Up 53.8
Post# of 273257
Posted On: 09/04/2016 3:21:00 AM
Agenus Inc (AGEN) 6.14 $AGEN
Antigenics Up 53.8% Since SmarTrend Uptrend Call (AGEN)
Comtex SmarTrend(R) - Wed Aug 31, 12:16AM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 3 months, Antigenics has returned 53.77% as of today's recent price of $6.42.
AGEN: 6.14 (-0.05)
Uptrend Call Working As Antigenics Stock Rises 45.4% (AGEN)
Comtex SmarTrend(R) - Tue Aug 23, 12:43PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 3 months, Antigenics has returned 45.39% as of today's recent price of $6.07.
AGEN: 6.14 (-0.05)
Why Agenus (AGEN) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:34AM CDT
Agenus (AGEN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
AGEN: 6.14 (-0.05)
Research Report Initiation on Biotech Stocks -- Agenus, ProNAi Therapeutics, Vanda Pharma, and Genocea Biosciences
PR Newswire - Thu Aug 11, 7:40AM CDT
This morning on Stock-Callers.com we have Biotech industry under review. This segment is focused on new drug developments and clinical researches. Stocks under evaluation are: Agenus Inc. (NASDAQ: AGEN), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Genocea Biosciences Inc. (NASDAQ: GNCA). Learn more about these stocks by downloading their free report at:
AGEN: 6.14 (-0.05), VNDA: 15.55 (+0.26), GNCA: 5.37 (+0.09), DNAI: 1.81 (unch)
Antigenics Has Returned 48.7% Since SmarTrend Recommendation (AGEN)
Comtex SmarTrend(R) - Mon Aug 08, 12:44PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 2 months, Antigenics has returned 48.74% as of today's recent price of $6.21.
AGEN: 6.14 (-0.05)
Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:32AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.76.
AGEN: 6.14 (-0.05), BIIB: 313.59 (+7.56), ICPT: 150.74 (+3.92)
Will Agenus (AGEN) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:27AM CDT
As of late, it has definitely been a great time to be an investor in Agenus Inc. (AGEN)
AGEN: 6.14 (-0.05)
Geron (GERN) Posts Narrower-Than-Expected Loss in Q2
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 9:04AM CDT
Investor focus will remain on Geron's (GERN) progress with the development of imetelstat.
AGEN: 6.14 (-0.05), JNJ: 119.32 (+0.24), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02)
Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Aerie (AERI) posted a wider-than-expected loss of 87 cents in the second-quarter 2016 loss.
AGEN: 6.14 (-0.05), ANIP: 59.86 (-1.56), AERI: 19.60 (+0.39), ANIK: 47.89 (-0.05)
Abeona Therapeutics (ABEO) in Focus: Stock Up 5.7% in Session
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:35AM CDT
Abeona Therapeutics Inc. (ABEO) was a big mover last session, as the company saw its shares rise around 6% on the day.
AGEN: 6.14 (-0.05), ABEO: 4.47 (+0.18)
Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 6.14 (-0.05), ANIP: 59.86 (-1.56), MRK: 62.98 (+0.08), NKTR: 18.45 (+0.34)
Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:43AM CDT
Agenus (AGEN) reported a loss of 24 cents in second-quarter of 2016, lower than the Zacks Consensus Estimate of 34 cents.
AGEN: 6.14 (-0.05)
Agenus Reports Second Quarter 2016 Financial Results and Operational Progress
BusinessWire - Thu Jul 28, 7:49AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.
AGEN: 6.14 (-0.05)
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
BusinessWire - Wed Jun 22, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-GITR agonist antibody INCAGN1876. The trial is being conducted by, and in collaboration with, Incyte Corporation.
AGEN: 6.14 (-0.05)
Agenus to Present at the 2016 JMP Securities Life Sciences Conference
BusinessWire - Wed Jun 15, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Robert B. Stein, M.D., Ph.D., President, Research & Development, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22nd at 3:30 p.m. ET. The conference will take place at the St. Regis New York in New York City.
AGEN: 6.14 (-0.05)
Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
BusinessWire - Thu Jun 09, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines, today announced the selection of a lead product candidate under its license and research collaboration with Merck. Merck, known as MSD outside the United States and Canada, has selected a lead antibody candidate and several backup antibodies, discovered by Agenus, to an undisclosed Merck checkpoint target. Based on this milestone and under the terms of the agreement, Agenus received a $2 million milestone payment from Merck.
AGEN: 6.14 (-0.05), MRK: 62.98 (+0.08)
Agenus to Webcast Annual Meeting of Stockholders
BusinessWire - Wed Jun 08, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Tuesday, June 14, 2016. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
AGEN: 6.14 (-0.05)
Agenus to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Garo H. Armen, Ph.D., Chairman and CEO, and Robert B. Stein, M.D., Ph.D., President, Research & Development, will present a corporate overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 9:30am ET.
AGEN: 6.14 (-0.05)
Antigenics Up 53.8% Since SmarTrend Uptrend Call (AGEN)
Comtex SmarTrend(R) - Wed Aug 31, 12:16AM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 3 months, Antigenics has returned 53.77% as of today's recent price of $6.42.
AGEN: 6.14 (-0.05)
Uptrend Call Working As Antigenics Stock Rises 45.4% (AGEN)
Comtex SmarTrend(R) - Tue Aug 23, 12:43PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 3 months, Antigenics has returned 45.39% as of today's recent price of $6.07.
AGEN: 6.14 (-0.05)
Why Agenus (AGEN) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:34AM CDT
Agenus (AGEN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
AGEN: 6.14 (-0.05)
Research Report Initiation on Biotech Stocks -- Agenus, ProNAi Therapeutics, Vanda Pharma, and Genocea Biosciences
PR Newswire - Thu Aug 11, 7:40AM CDT
This morning on Stock-Callers.com we have Biotech industry under review. This segment is focused on new drug developments and clinical researches. Stocks under evaluation are: Agenus Inc. (NASDAQ: AGEN), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Genocea Biosciences Inc. (NASDAQ: GNCA). Learn more about these stocks by downloading their free report at:
AGEN: 6.14 (-0.05), VNDA: 15.55 (+0.26), GNCA: 5.37 (+0.09), DNAI: 1.81 (unch)
Antigenics Has Returned 48.7% Since SmarTrend Recommendation (AGEN)
Comtex SmarTrend(R) - Mon Aug 08, 12:44PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 2 months, Antigenics has returned 48.74% as of today's recent price of $6.21.
AGEN: 6.14 (-0.05)
Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:32AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.76.
AGEN: 6.14 (-0.05), BIIB: 313.59 (+7.56), ICPT: 150.74 (+3.92)
Will Agenus (AGEN) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:27AM CDT
As of late, it has definitely been a great time to be an investor in Agenus Inc. (AGEN)
AGEN: 6.14 (-0.05)
Geron (GERN) Posts Narrower-Than-Expected Loss in Q2
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 9:04AM CDT
Investor focus will remain on Geron's (GERN) progress with the development of imetelstat.
AGEN: 6.14 (-0.05), JNJ: 119.32 (+0.24), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02)
Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Aerie (AERI) posted a wider-than-expected loss of 87 cents in the second-quarter 2016 loss.
AGEN: 6.14 (-0.05), ANIP: 59.86 (-1.56), AERI: 19.60 (+0.39), ANIK: 47.89 (-0.05)
Abeona Therapeutics (ABEO) in Focus: Stock Up 5.7% in Session
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:35AM CDT
Abeona Therapeutics Inc. (ABEO) was a big mover last session, as the company saw its shares rise around 6% on the day.
AGEN: 6.14 (-0.05), ABEO: 4.47 (+0.18)
Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 6.14 (-0.05), ANIP: 59.86 (-1.56), MRK: 62.98 (+0.08), NKTR: 18.45 (+0.34)
Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:43AM CDT
Agenus (AGEN) reported a loss of 24 cents in second-quarter of 2016, lower than the Zacks Consensus Estimate of 34 cents.
AGEN: 6.14 (-0.05)
Agenus Reports Second Quarter 2016 Financial Results and Operational Progress
BusinessWire - Thu Jul 28, 7:49AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.
AGEN: 6.14 (-0.05)
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
BusinessWire - Wed Jun 22, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-GITR agonist antibody INCAGN1876. The trial is being conducted by, and in collaboration with, Incyte Corporation.
AGEN: 6.14 (-0.05)
Agenus to Present at the 2016 JMP Securities Life Sciences Conference
BusinessWire - Wed Jun 15, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Robert B. Stein, M.D., Ph.D., President, Research & Development, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22nd at 3:30 p.m. ET. The conference will take place at the St. Regis New York in New York City.
AGEN: 6.14 (-0.05)
Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
BusinessWire - Thu Jun 09, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines, today announced the selection of a lead product candidate under its license and research collaboration with Merck. Merck, known as MSD outside the United States and Canada, has selected a lead antibody candidate and several backup antibodies, discovered by Agenus, to an undisclosed Merck checkpoint target. Based on this milestone and under the terms of the agreement, Agenus received a $2 million milestone payment from Merck.
AGEN: 6.14 (-0.05), MRK: 62.98 (+0.08)
Agenus to Webcast Annual Meeting of Stockholders
BusinessWire - Wed Jun 08, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Tuesday, June 14, 2016. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
AGEN: 6.14 (-0.05)
Agenus to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Garo H. Armen, Ph.D., Chairman and CEO, and Robert B. Stein, M.D., Ph.D., President, Research & Development, will present a corporate overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 9:30am ET.
AGEN: 6.14 (-0.05)
(0)
(0)Scroll down for more posts ▼